Evidence map›Paper›PMID 35251770›Full record

ArticleOncoimmunology2022

Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.

Alexandr V Bazhin, Katharina von Ahn, Jasmin Fritz, Henriette Bunge, Caroline Maier, Orkhan Isayev, Florian Neff, Jens T Siveke, Svetlana Karakhanova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Alexandr V BazhinDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Katharina von AhnDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Jasmin FritzDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Henriette BungeDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Caroline MaierDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Orkhan IsayevDepartment of Cytology, Embryology and Histology, Azerbaijan Medical University, Baku, Azerbaijan.
Florian NeffDivision of Solid Tumor Translational Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site University Hospital Essen, Heidelberg, Germany.
Jens T SivekeDivision of Solid Tumor Translational Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site University Hospital Essen, Heidelberg, Germany.ORCID 0000-0002-8772-4778
Svetlana KarakhanovaDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEAzerbaijan Medical University · AZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint molecule B7-H1 plays a decisive immune regulatory role in different pathologies including cancer, and manipulation of B7-H1 expression became an attractive approach in cancer immunotherapy. Pancreatic cancer (PDAC) is characterized by pronounced immunosuppressive environment and B7-H1 expression correlates with PDAC prognosis. However, the first attempts to diminish B7-H1 expression in patients were not so successful. This points the complicity of PDAC immunosuppressive network and requires further examinations. We investigated the effect of B7-H1 deficiency in PDAC. Our results clearly show that partial or complete B7-H1 inhibition in vivo let to reduced tumor volume and improved survival of PDAC-bearing mice. This oncological benefit is due to the abrogation of immunosuppression provided by MDSC, macrophages, DC and Treg, which resulted in simultaneous restoration of anti-tumor immune response, namely improved accumulation and functionality of effector-memory CD4 and CD8 T cells. Our results underline the potential of B7-H1 molecule to control immunosuppressive network in PDAC and provide new issues for further clinical investigations.

Indexed as

B7-H1 AntigenCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsHumansImmune Checkpoint InhibitorsImmunotherapyMiceProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanCd274 protein, mouseImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 knockoutB7-H1 (PD-L1)cancer immunotherapyimmune checkpoint moleculesimmunosuppressionpancreatic cancer

Identifiers

PMID35251770
PMCPMC8890402
OpenAlexW4214496068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.